PharmacoEconomics & Outcomes News

, Volume 770, Issue 1, pp 11–11 | Cite as

Docetaxel, zoledronic acid not cost effective for prostate cancer

Clinical study
  • 14 Downloads

Reference

  1. Zhang P, et al. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis. Tumori : 22 Nov 2016. Available from: URL: http://doi.org/10.5301/tj.5000583

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations